Key result
Sesamol at 50 mg/kg bw provided significant cardioprotection against doxorubicin-induced cardiomyopathy in rats through antioxidant, lipid-lowering, and membrane stabilization effects.
Why the study?
Does sesamol prevent doxorubicin-induced cardiomyopathy in experimental rats?
Population
Experimental rats with doxorubicin-induced cardiomyopathy
Design
Preclinical
Follow-up
21 days
Authors
Loading...
Should not inform clinical use; leaves open translation of rat cardioprotection to human doxorubicin therapy.
Does sesamol prevent doxorubicin-induced cardiomyopathy in experimental rats?
In a rat model, sesamol protected against doxorubicin-induced cardiomyopathy by ameliorating oxidative stress, lowering lipids, and stabilizing membranes.
Chennuru et al. (2013) studied Doxorubicin-induced cardiomyopathy. Sesamol was evaluated on Cardioprotective effect (biochemical parameters and histopathology). Sesamol at 50 mg/kg bw provided significant cardioprotection against doxorubicin-induced cardiomyopathy in rats through antioxidant, lipid-lowering, and membrane stabilization effects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: